Firstly, fluid-based measurements—notably urinary HMGB1 and urinary VEGF in bladder cancer and serum or tissue assessments of GDF15, HSP90, and S100A9 in renal tumors—provide viable, minimally invasive opportunities to complement imaging and histopathology. This evidence concerns the gene HSP90AA1 and urinary bladder cancer.